Zobrazeno 1 - 10
of 25
pro vyhledávání: '"I P Barton"'
Publikováno v:
Arthritis and Rheumatism, 48, 3224-9
Arthritis and Rheumatism, 48, 11, pp. 3224-9
Arthritis and Rheumatism, 48, 11, pp. 3224-9
Item does not contain fulltext OBJECTIVE: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs). METHODS: Data were obtained from 2 randomized clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81458b8727f19ba7e2808ffc8fb70b1
https://ora.ox.ac.uk/objects/uuid:d3f48feb-78ad-410f-be1e-b8e91e7c9352
https://ora.ox.ac.uk/objects/uuid:d3f48feb-78ad-410f-be1e-b8e91e7c9352
Publikováno v:
Osteoporosis International
Summary This posthoc analysis of four trials studied the efficacy of risedronate to reduce fragility fractures in postmenopausal women with osteopenia (i.e., T-scores between −1 and −2.5). Risedronate reduced the fracture risk by 73% ( = 0.023) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355ea2effe1bc63c2dd7385e9cd308ec
https://doi.org/10.1007/s00198-007-0493-y
https://doi.org/10.1007/s00198-007-0493-y
Publikováno v:
Osteoporosis International. 17:212-216
Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc26cb28c5e66c8b6480c6d543d93b1f
https://doi.org/10.1007/s00198-005-1975-4
https://doi.org/10.1007/s00198-005-1975-4
Publikováno v:
Journal of Bone and Mineral Research. 20:2105-2115
The incidences of osteoporosis and renal insufficiency increase with age. We studied the influence of renal function on the safety and efficacy of risedronate 5 mg daily in osteoporotic women. Risedronate was safe and effective in osteoporotic women
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c5f23948d2e55881aacc176598af3b
https://doi.org/10.1359/jbmr.050817
https://doi.org/10.1359/jbmr.050817
Publikováno v:
Osteoporosis International, 16, 1291-8
Osteoporosis International, 16, 10, pp. 1291-8
Osteoporosis International, 16, 10, pp. 1291-8
Contains fulltext : 47480.pdf (Publisher’s version ) (Closed access) Most osteoporosis treatments have proven efficacy in reducing the risk of vertebral fractures, whereas evidence is less straightforward for prevention of non-vertebral fractures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11445d121ef2ad1d5c707f786201bc1b
https://doi.org/10.1007/s00198-005-1945-x
https://doi.org/10.1007/s00198-005-1945-x
Publikováno v:
Osteoporosis International. 16:475-482
The aim of this study was to examine the effects of risedronate (5 mg/daily) in patients identified solely on the basis of a prior fragility fracture, without BMD as an inclusion criterion. A total of 1,802 patients were examined from the VERT-NA and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cdd0b555bdbdeaa3376b81770a1931
https://doi.org/10.1007/s00198-004-1698-y
https://doi.org/10.1007/s00198-004-1698-y
Autor:
Patrice Fardellone, M. L. Brandi, Steven Boonen, I P Barton, L-G Ste-Marie, Roberto Civitelli, J. T. Harrington, Andreas Grauer
Publikováno v:
Calcified Tissue International. 74:129-135
Prevention of nonvertebral fractures, which account for a substantial proportion of osteoporotic fractures, is an important goal of osteoporosis treatment. Risedronate, a pyridinyl bisphosphonate, significantly reduces clinical vertebral fracture inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e87ac7842c6e61a38bb71c0ee11ff9c
https://doi.org/10.1007/s00223-003-0042-4
https://doi.org/10.1007/s00223-003-0042-4
Autor:
I P Barton
Publikováno v:
Pharmaceutical Statistics. 3:205-212
There is debate within the osteoporosis research community about the relationship between the risk of osteoporotic fracture and the surrogate measures of fracture risk. Meta-regression analyses based on summary data have shown a linear relationship b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad802a17c8f3f9aee32220c1b32b864c
https://doi.org/10.1002/pst.123
https://doi.org/10.1002/pst.123
Publikováno v:
Journal of Bone and Mineral Research. 19:323-329
It is unclear whether the antifracture efficacy of bisphosphonates depends on pretreatment bone turnover. We analyzed the risedronate phase III clinical programs using the urinary excretion of deoxypyridinoline (uDPD) as an index of pretreatment bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16026dd039c68fad7d646d1ee3f13655
https://doi.org/10.1359/jbmr.0301231
https://doi.org/10.1359/jbmr.0301231
Autor:
Rosemary A. Hannon, R. Eastell, I P Barton, P. Garnero, Chines Arkadi Aaron, Pierre D. Delmas
Publikováno v:
Journal of Bone and Mineral Research. 18:1051-1056
Changes in the level of biochemical markers of bone resorption with risedronate treatment for osteoporosis were examined as a surrogate for the decrease in fracture risk. Greater decreases in bone resorption markers were associated with greater decre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a9084aff6bd6571093ec4421013380
https://doi.org/10.1359/jbmr.2003.18.6.1051
https://doi.org/10.1359/jbmr.2003.18.6.1051